AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04898322
Drug: SY-005
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg of SY-005 for each dose，doses to be given every 12 hours over a period of 5 days
Trial: NCT04730856
Drug: Tinzaparin
RxNorm normalized name: Tinzaparin
DrugBank: Tinzaparin (DB06822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home.
Trial: NCT05234190
Drug: QEL-001
RxNorm normalized name: Qelbree
DrugBank: Viloxazine (DB09185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QEL-001 is an autologous therapy that is composed of engineered regulatory T cells transduced with a lentiviral vector containing a CAR directed against HLA-A2. Treatment will be given via an IV infusion.
Trial: NCT05629364
Drug: KIO-101
RxNorm normalized name: KIO-301
DrugBank: KIO-301 (DB18465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized, Controlled
Trial: NCT06465433
Drug: Tafasitamab
RxNorm normalized name: Tafasitamab
DrugBank: Tafasitamab (DB15044)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
Trial: NCT06288152
Drug: Sodium Thiosulfate
RxNorm normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 mL administered
Trial: NCT00508963
Drug: sodium stibogluconate (Pentostam)
RxNorm normalized name: sodium stibogluconate
DrugBank: Sodium stibogluconate (DB05630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/kg IV every day for 20 or 28 days
Trial: NCT05337345
Drug: Cendakimab
RxNorm normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified Dose on Specified Days
Trial: NCT05545072
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dupilumab will be administered subcutaneously at a dose of 300 milligrams (mg) in a 2 milliliter (mL) solution every 2 weeks until the end of treatment (EOT) at Week 52. Participants will receive a total of 26 doses.
Trial: NCT06527781
Drug: PD5K3
RxNorm normalized name: Phendimetrazine
DrugBank: Phendimetrazine (DB01579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six dose levels will be evaluated. intravenous injection
Trial: NCT06527781
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Six dose levels will be evaluated. intramuscular injection
Trial: NCT04854551
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naltrexone is an opioid antagonist with primary action at the mu opioid receptor.
Trial: NCT05279092
Drug: Bupivacaine-Liposomal Bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adductor canal block comprised of 20 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 30 ml; 10 ml 0.25% plain bupivacaine + 10 ml LB (133 mg) with the total volume of 20 ml will be administered through an iPACK block
Trial: NCT05279092
Drug: Bupivacaine -Dexamethasone Sodium Phosphate-Methylprednisolone Acetate
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adductor canal block comprised of 30 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml); 20 ml 0.25% plain bupivacaine + 5 mg DEX (0.5 ml) and 40 mg MPA (1 ml) will be administered through an iPACK block.
Trial: NCT05903027
Drug: Rimegepant 75 MG Disintegrating Oral Tablet
RxNorm normalized name: rimegepant 75 MG Disintegrating Oral Tablet
DrugBank: Rimegepant (DB12457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients using Rimegepant 75 mg orally disintegrating tablet to treat acute migraine attacks
Trial: NCT04523857
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)
Trial: NCT04523857
Drug: Hydroxychloroquine
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)
Trial: NCT04218409
Drug: OxyCODONE 5 mg Oral Tablet
RxNorm normalized name: oxyCODONE 5 mg oral tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral oxycodone 5 mg orally
Trial: NCT04218409
Drug: Oxytocin nasal spray
RxNorm normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin administration (48 IU)
Trial: NCT04218409
Drug: OxyCODONE 2.5 mg Oral Tablet
RxNorm normalized name: ASA 325 MG / Oxycodone 2.5 MG Oral Tablet
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral oxycodone 2.5 mg orally
Trial: NCT06540963
Drug: Tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT06540963
Drug: Naxitamab
RxNorm normalized name: Naxitamab
DrugBank: Naxitamab (DB15965)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT05236608
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered together with ADG106 via intravenous infusion.
Trial: NCT04713163
Drug: covid19 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine
Trial: NCT06097663
Drug: MAS825
RxNorm normalized name: MAS825
DrugBank: MAS825 (DB16452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active MAS825 single dose
Trial: NCT06097663
Drug: MAS825 Placebo
DrugBank: MAS825 (DB16452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAS825 placebo single dose
Trial: NCT06097663
Drug: DFV890
RxNorm normalized name: DFV890
DrugBank: DFV890 (DB16461)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet of DFV890 active once daily
Trial: NCT06097663
Drug: DFV890 placebo
DrugBank: DFV890 (DB16461)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet of DFV890 placebo once daily
Trial: NCT06492889
Drug: Levonorgestrel
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants in the levonorgestrel plus mifepristone group will receive one tablet of 1.5 mg levonorgestrel
Trial: NCT06492889
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in both groups will receive one tablet of 200 mg mifepristone
Trial: NCT04922658
Drug: Surufatinib
RxNorm normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surufatinib,300mg, qd, po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.
Trial: NCT04922658
Drug: Surufatinib Plus Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Surufatinib, 250mg, qd, po; Plus Vinorelbine, 20 mg, every 2 days; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.
Trial: NCT05369793
Drug: Alpha lipoic acid
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of alpha-lipoic acid 600mg plus vildagliptin/metformin combination (50/1000mg) orally once daily for 3 months.
Trial: NCT05079061
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sublingual misoprostol 600 micrograms in addition routine uterotonics at third stage of labour
Trial: NCT05369793
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administration of 500 mcg plus vildagliptin/metformin combination(50/1000mg) orally once daily for 3 months.
Trial: NCT05783492
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/kg single dose in 0.5 mL sprays in each nare separated by 60 seconds
Trial: NCT05493124
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other drugs that may have therapeutic effects
Trial: NCT04498468
Drug: Sustained Release Dexamethasone, 0.4 mg
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 0.4mg lacrimal insert
Trial: NCT05156450
Drug: TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treatment with TQB3616 in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer.
Trial: NCT05451017
Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fed condition
RxNorm normalized name: 17-hydroxy-19-nor-17-α-pregn-4-en-20-yn-3-one
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single dose of 1 mg AEF0117 in fed condition
Trial: NCT05451017
Drug: 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one in fasting condition
RxNorm normalized name: 17-hydroxy-19-nor-17-α-pregn-4-en-20-yn-3-one
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a single dose of 1 mg AEF0117 in fasting condition
Trial: NCT04904341
Drug: Cerebrolysin
RxNorm normalized name: cerebrolysin
DrugBank: Cerebrolysin (DB16599)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: neuroprotection treatment
Trial: NCT04827810
Drug: Gamitrinib
RxNorm normalized name: Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a first-in-human, phase I, open-label, non-randomized dose-escalation and dose-expansion study with the primary objective to determine the safety profile of small molecule, mitochondrial-targeted Hsp90 inhibitor, gamitrinib, including identification of dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) in patients with advanced cancers. A secondary objective of the study is to determine the recommended dose and regimen(s) for a phase II study. This study is based on preclinical data demonstrating the anticancer activity, unique mechanism of action and preliminary safety of gamitrinib.
Trial: NCT00270426
Drug: Benazepril
RxNorm normalized name: Benazepril
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01835314
Drug: Stiripentol
RxNorm normalized name: Stiripentol
DrugBank: Stiripentol (DB09118)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
Trial: NCT06217848
Drug: Saxenda
RxNorm normalized name: Saxenda
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive subcutaneous injections of Saxenda 18 mg/3 mL Pen (liraglutide_obesity) starting at 0.6 mg qd. Increase by 0.6 mg qd at weekly intervals to 1.2 mg qd in week 2, 1.8 mg qd in week 3, 2.4 mg qd in week 4, 3.0 mg qd in week 5, and maintain for 8 weeks at a maximally tolerated dose within 3.0 mg starting in week 5. If the subject's response to treatment does not allow for escalation to the planned dose, subjects will inject an adaptive maximally tolerated dose within the planned dose at each cycle. Total duration of Saxenda treatment is 12 weeks.
Trial: NCT06350006
Drug: SHR-A1904; Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab
Trial: NCT06350006
Drug: SHR-A1904; CAPOX; Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)
Trial: NCT03843892
Drug: OFEV
RxNorm normalized name: Ofev
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: twice daily
Trial: NCT05309902
Drug: Soticlestat
RxNorm normalized name: Soticlestat
DrugBank: Soticlestat (DB16987)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soticlestat tablet.
Trial: NCT05309902
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin over-encapsulated tablet.
Trial: NCT04683159
Drug: Brimonidine Tartrate 0.15% Oph Soln
RxNorm normalized name: BRIMONIDINE TARTRATE 0.15% OPH SOLN
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop of brimonidine 0.15% (\~0.05mL) 15 minutes prior to surgery
Trial: NCT04683159
Drug: Brimonidine Tartrate 0.025% Oph Soln
RxNorm normalized name: BRIMONIDINE TARTRATE 0.025% OPH SOLN
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 drop of brimonidine 0.025% (\~0.05mL) 15 minutes prior to surgery
Trial: NCT04347135
Drug: F-18 FES
RxNorm normalized name: F-18 Fes
DrugBank: Fluoroestradiol F-18 (DB15690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F-18 FES PET/MRI for detection of endometriosis.
Trial: NCT05976802
Drug: High dose budesonide rectal foam
RxNorm normalized name: budesonide Rectal Foam
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Trial: NCT05976802
Drug: Low dose budesonide rectal foam
RxNorm normalized name: budesonide Rectal Foam
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Twice a day for 2 weeks, then once a day for 4 weeks
Trial: NCT05565391
Drug: Elranatamab
RxNorm normalized name: ELRANATAMAB
DrugBank: Elranatamab (DB15395)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCMA-CD3 bispecific antibody
Trial: NCT06506292
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab:1200 mg, iv, d1
Trial: NCT05932472
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin at currently prescribed dose
Trial: NCT04678830
Drug: Leronlimab (700mg)
RxNorm normalized name: Leronlimab
DrugBank: Leronlimab (DB05941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)
Trial: NCT04789915
Drug: Memantine
RxNorm normalized name: Memantine
DrugBank: Memantine (DB01043)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Add on treatment with memantine to aripiprazole.
Trial: NCT05779007
Drug: Pirfenidone
RxNorm normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pirfenidone
Trial: NCT05779007
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nintedanib
Trial: NCT04642391
Drug: Cosyntropin
RxNorm normalized name: Cosyntropin
DrugBank: Tetracosactide (DB01284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administer 0.25mg Cosyntropin to determine adrenal sufficiency vs. insufficiency in patients with decompensated cirrhosis
Trial: NCT05068427
Drug: Chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20mg or 30mg orally twice per week(BIW)
Trial: NCT05068427
Drug: Envafolimab
RxNorm normalized name: Envafolimab
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg subcutaneous infusions every 4 weeks
Trial: NCT04823442
Drug: Mirabegron
RxNorm normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirabegron: a single dose of 200 mg mirabegron (4 tablets of 50 mg)
Trial: NCT04823442
Drug: Bisoprolol Fumarate
RxNorm normalized name: Bisoprolol Fumarate
DrugBank: Bisoprolol (DB00612)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a single dose of 10 mg (2 tablets of 5 mg)
Trial: NCT06426303
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week randomized double blinded placebo-controlled drug trial titrating drug/placebo dose after 1 week.
Trial: NCT04865419
Drug: Voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Voriconazole film-coated tablet will be administered orally.
Trial: NCT04991974
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine is an FDA-approved medication for opioid dependence, and will be used in this study consistent with its approved use (but will be initiated in the novel setting of sexual health clinics in this health services study).~Participants will meet with an sexual health clinic provider who holds a waiver to prescribe buprenorphine. Participants will initiate buprenorphine treatment via a home induction under the direction of the provider. Because barriers to transfer may take some time to overcome, participants will be able to receive additional bridge buprenorphine up to two times (up to 15 days' supply at a time) until successful transfer to OUD treatment in the community.
Trial: NCT00001994
Drug: Atovaquone
RxNorm normalized name: Atovaquone
DrugBank: Atovaquone (DB01117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06315400
Drug: Ingavirin®
DrugBank: Ingavirin (DB11944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/day for 5 days
Trial: NCT05097781
Drug: PD-1 blocking antibody
RxNorm normalized name: Humanized pd-1 blocking antibody hx-008
DrugBank: Pucotenlimab (DB17552)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients with more than one distant metastatic lesions will accept at least one site of radiotherapy and PD-1 blockade at the same time.
Trial: NCT06345560
Drug: Drospirenone
RxNorm normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4 mg tablet once daily
Trial: NCT06553248
Drug: GZR4
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered once weekly subcutaneously (s.c., under the skin) for 6 weeks
Trial: NCT06553248
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered once daily subcutaneously (s.c., under the skin) for 6 weeks
Trial: NCT05126329
Drug: amcenestrant
RxNorm normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet for oral use
Trial: NCT06631976
Drug: Nerve block with 4ml of 2% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nerve block with 4ml of 2% lidocaine around the suprascapular nerve
Trial: NCT06629051
Drug: Berberine Hydrochloride
RxNorm normalized name: Berberine Hydrochloride
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: post-intervention of berberine
Trial: NCT05230901
Drug: Dihydralazine
RxNorm normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with CMR-derived ECV% levels ≥25.9% in arm Spironolactone + Dihydralazine will receive spironolactone 25 mg/d + dihydralazine (2x12.5 mg/d p.o. in slow acethylators, and 2x25mg/d p.o. in fast acethylators, confirmed by genetic testing)
Trial: NCT05306587
Drug: Darzalex
RxNorm normalized name: Darzalex
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Investigate the home administration of Darzalex SC reported by both patients and healthcare professionals compared to the hospital administration setting.
Trial: NCT04694248
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For anticoagulant, it is rivaroxaban 20mg once a day for 6 months.
Trial: NCT04694248
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For antiplatelet therapy, it is aspirin 100mg once a day indefinitely.
Trial: NCT04977128
Drug: 89Zr-KN035
RxNorm normalized name: 89ZR-BEVACIZUMAB
DrugBank: Bevacizumab zirconium Zr-89 (DB14907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive a tracer (10 mg, IV) dose of Zr-89 (2-3mCi) labelled KN035 (89Zr- KN035)
Trial: NCT04731051
Drug: HCQ01
RxNorm normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCQ01 is a sterile, clear and colorless, ready-to-use aqueous nebulizer solution. Hydroxychloroquine sulfate administered via nebulization
Trial: NCT05919888
Drug: Povidone-Iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Applied to skin incision.
Trial: NCT00001011
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000442
Drug: naltrexone (Revia)
RxNorm normalized name: naltrexone Oral Tablet [ReVia]
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06360042
Drug: Adebrelimab plus Apatinib
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab 1200mg intravenously every 3 weeks plus Apatinib 250mg orally once daily
Trial: NCT06360042
Drug: Adebrelimab plus Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adebrelimab 1200mg intravenously plus Bevacizumab 15 mg/kg intravenously every 3 weeks